Search results for " Endometrial Cancer"

showing 9 items of 9 documents

ASO Author Reflections: How Long will We Perform Lymphadenectomy in Endometrial Cancer Patients?

2022

Abstract Objectives To compare survival and progression outcomes between 2 nodal assessment approaches in patients with nonbulky stage IIIC endometrial cancer (EC). Methods Patients with stage IIIC EC treated at 2 institutions were retrospectively identified. At 1 institution, a historical series (2004–2008) was treated with systematic pelvic and para-aortic lymphadenectomy (LND cohort). At the other institution, more contemporary patients (2006–2013) were treated using a sentinel lymph node algorithm (SLN cohort). Outcomes (hazard ratios [HRs]) within the first 5 years after surgery were compared between cohorts using Cox models adjusted for type of adjuvant therapy. Results The study incl…

0301 basic medicineN.A.medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeMEDLINEArticleEndometrial CancerDisease-Free Survival03 medical and health sciences0302 clinical medicineLymphadenectomy Endometrial CancerSurgical oncologyAdjuvant therapymedicineHumansStage IIICNeoplasm InvasivenessProgression-free survivalLymph nodeAgedNeoplasm StagingRetrospective Studiesbusiness.industryEndometrial cancerGeneral surgeryObstetrics and GynecologyLymphadenectomymedicine.diseaseEndometrial Neoplasms030104 developmental biologymedicine.anatomical_structureTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIASentinel nodeOncology030220 oncology & carcinogenesisLymphatic MetastasisDisease ProgressionLymph Node ExcisionFemaleSurgeryLymphadenectomySentinel Lymph NodebusinessAlgorithmChemoradiotherapyAlgorithmsAnnals of Surgical Oncology
researchProduct

How Technology Can Impact Surgeon Performance: A Randomized Trial Comparing 3-Dimensional versus 2-Dimensional Laparoscopy in Gynecology Oncology

2016

This randomized clinical trial (Canadian Task Force classification I) aimed to compare 2-dimension (2-D) versus 3-dimensional (3-D) laparoscopic hysterectomy and pelvic lymphadenectomy in endometrial and cervical cancer patients. Between December 2014 and March 2015, 90 patients were enrolled: 29 (32.2%) with early or locally advanced cervical cancer after neoadjuvant treatment and 61 (67.8%) with early-stage endometrial cancer. Patients were randomly assigned to undergo 2-D (Group A, n = 48 [53.3%]) or 3-D (Group B, n = 42 [46.7%)]) laparoscopy. Baseline characteristics were superimposable in the 2 groups. Median operative time was similar in the 2 groups. Median estimated blood loss durin…

Adultmedicine.medical_specialtymedicine.medical_treatmentOperative TimeUterine Cervical NeoplasmsHysterectomylaw.invention03 medical and health sciencesImaging Three-DimensionalPostoperative Complications0302 clinical medicineRandomized controlled trialEndometrial cancerlawThree-dimensional laparoscopicmedicineHumansLaparoscopyNeoadjuvant therapyCervical cancer; Endometrial cancer; Three-dimensional laparoscopicAgedSurgeonsGynecologyCervical cancerHysterectomymedicine.diagnostic_testbusiness.industryEndometrial cancerGeneral surgeryObstetrics and GynecologyPerioperativeMiddle Agedmedicine.diseaseNeoadjuvant TherapyEndometrial NeoplasmsSurgery030220 oncology & carcinogenesisCervical cancerLymph Node ExcisionFemaleLaparoscopy030211 gastroenterology & hepatologyLymphadenectomyClinical CompetenceCervical cancer; Endometrial cancer; Three-dimensional laparoscopic; Obstetrics and Gynecologybusiness
researchProduct

Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Stu…

2020

ABSTRACT Study Objective The primary aim of our study was to investigate the incidence of endometrial pathologies, especially endometrial cancer, in women with breast cancer treated with tamoxifen (TAM), aromatase inhibitors (AIs), or receiving no treatment (NT). The secondary aim was to identify, in this cohort, ultrasonographic findings that represent robust indications for hysteroscopy and endometrial biopsy, to avoid unnecessary second-level diagnostic procedures. Design Multicenter retrospective cohort study (Clinical Trial ID: NCT03898947). Setting Data were collected from different Italian centers: Regina Elena National Cancer Institute of Rome, Arbor Vitae Centre of Rome, Gaetano Ma…

BiopsyAromatase inhibitors Breast cancer Endometrial cancer Endometrial pathologies Tamoxifen Adult Aged Aged 80 and over Antineoplastic Agents Hormonal Biopsy Breast Neoplasms Cohort Studies Endometrial Hyperplasia Endometrial Neoplasms Endometrium Female Humans Hysteroscopy Incidence Middle Aged Polyps Precancerous Conditions Pregnancy Retrospective Studies Tamoxifen Uterine Diseases Uterine NeoplasmsCohort StudiesEndometrium0302 clinical medicineBreast cancerEndometrial cancerPregnancyAromatase inhibitors; Breast cancer; Endometrial cancer; Endometrial pathologies; TamoxifenAged 80 and overUterine Diseases030219 obstetrics & reproductive medicinemedicine.diagnostic_testEndometrial pathologiesIncidenceObstetrics and GynecologyMiddle AgedAromatase inhibitorsHysteroscopy030220 oncology & carcinogenesisEndometrial HyperplasiaUterine NeoplasmsFemalemedicine.drugAromatase inhibitors Breast cancer Endometrial cancer Endometrial pathologies TamoxifenAdultmedicine.medical_specialtyAntineoplastic Agents HormonalBreast NeoplasmsHysteroscopy03 medical and health sciencesBreast cancerPolypsmedicineEndometrial PolypHumansAgedRetrospective StudiesGynecologybusiness.industryEndometrial cancerCancerRetrospective cohort studymedicine.diseaseEndometrial NeoplasmsTamoxifenbusinessPrecancerous ConditionsTamoxifenEndometrial biopsy
researchProduct

Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients.

2014

ObjectiveThe aim of our study was to evaluate morbidity, mortality, and long-term survival of patients who underwent pelvic exenteration (PE) with curative intent for recurrence of endometrial adenocarcinoma during a single decade.MethodsWe defined a cohort of 21 patients who met our inclusion criteria, referred to 4 cooperating gynecologic oncology settings in Germany and Italy between 2000 and 2011. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until the last follow-up or death.ResultsThe median age was 66 years. A total of 42.9% of the patients had major complications, and a compl…

Pelvic Neoplasmmedicine.medical_specialtySurvivalPrognosimedicine.medical_treatmentendometrial adenocarcinomaGynecologic oncologyAdenocarcinomaFollow-Up StudieRetrospective StudiemedicineHumansEndometrial NeoplasmPelvic NeoplasmsSurvival rateAgedNeoplasm StagingPelvic NeoplasmsRetrospective StudiesAged 80 and overPelvic exenteration recurrent endometrial adenocarcinomaPelvic exenterationbusiness.industryMedicine (all)Endometrial cancerGeneral surgeryObstetrics and GynecologyRecurrent endometrial cancerRetrospective cohort studyPerioperativeMiddle Agedmedicine.diseasePrognosisSurgeryEndometrial Neoplasmspelvic exenterationSurvival RateSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyCohortFemaleMorbidityNeoplasm Recurrence LocalbusinessHumanFollow-Up Studies
researchProduct

Fertility-sparing approach in women affected by stage i and low-grade endometrial carcinoma: An updated overview

2021

Endometrial cancer (EC) is a deleterious condition which strongly affects a woman’s quality of life. Although aggressive interventions should be considered to treat high-grade EC, a conservative approach should be taken into consideration for women wishing to conceive. In this scenario, we present an overview about the EC fertility-sparing approach state of art. Type I EC at low stage is the only histological type which can be addressed with a fertility-sparing approach. Moreover, no myometrium and/or adnexal invasion should be seen, and lymph-vascular space should not be involved. Regarding the pharmaceutical target, progestins, in particular medroxyprogesterone acetate (MPA) or megestrol …

Psychological interventionReviewIUDQuality of lifeEndometrial cancerMedroxyprogesterone acetateFertility preservationBiology (General)Fertility preservationSpectroscopyObstetricsFertility PreservationGeneral Medicinefertility sparingART; Endometrial cancer; Fertility preservation; Fertility sparing; Infertility; IUD; Metformin; ProgestinMetforminComputer Science ApplicationsChemistryMyometriumFemaleARTmedicine.drugHumanInfertilityAdultmedicine.medical_specialtyQH301-705.5medicine.drug_classFertility sparingMedroxyprogesterone AcetateCatalysisInorganic ChemistrymedicineHumansEndometrial NeoplasmPhysical and Theoretical ChemistryQD1-999Molecular BiologyNeoplasm Staging...business.industryEndometrial cancerOrganic Chemistrymedicine.diseaseEndometrial NeoplasmsProgestinFertilityMegestrol acetateInfertilityQuality of LifeProgestinsbusinessProgestin
researchProduct

Sentinel Lymph Node in Aged Endometrial Cancer Patients “The SAGE Study”: A Multicenter Experience

2021

ObjectiveThe incidence of endometrial cancer is increasing in elderly people. Considering that aging progressively affects lymphatic draining function, we aimed to define its impact on IGC uptake during SLN mapping.MethodsA multicenter retrospective cohort of endometrial cancer patients with apparently early-stage endometrial cancer undergoing complete surgical staging with SLN dissection was identified in four referral cancer centers from May 2015 to March 2021. Patients were classified in Group 1 (<65 years old) and Group 2 (≥65 years old). The primary endpoint was the assessment of the overall, bilateral, and unsuccessful SLN mapping in the two groups. Secondary outcomes were the …

aged populationCancer Researchmedicine.medical_specialtyindocyanine greenSentinel lymph nodesentinel lymph node (SLN)Logistic regressionelderlylymphatic anatomyInternal medicineClinical endpointMedicineRisk factorRC254-282Original Researchbusiness.industryIncidence (epidemiology)Endometrial cancerCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studymedicine.diseaseSettore MED/40 - GINECOLOGIA E OSTETRICIAaged population; elderly; endometrial cancer; indocyanine green; lymphatic anatomy; sentinel lymph node (SLN)Oncologyendometrial cancerbusiness
researchProduct

Beyond Sentinel Lymph Node: Outcomes of Indocyanine Green-Guided Pelvic Lymphadenectomy in Endometrial and Cervical Cancer

2023

Background: The aim of our study was to compare the number of lymph nodes removed during indocyanine green (ICG)-guided laparoscopic/robotic pelvic lymphadenectomy with standard systematic lymphadenectomy in endometrial cancer (EC) and cervical cancer (CC). Methods: This is a multicenter retrospective comparative study (Clinical Trial ID: NCT04246580; updated on 31 January 2023). Women affected by EC and CC who underwent laparoscopic/robotic systematic pelvic lymphadenectomy, with (cases) or without (controls) the use of ICG tracer injection within the uterine cervix, were included in the study. Results: The two groups were homogeneous for age (p = 0.08), Body Mass Index, International Fede…

indocyanine greenRobotic surgery.pelvic lymphadenectomycervical cancerHealth Toxicology and Mutagenesisendometrial cancerrobotic surgeryPublic Health Environmental and Occupational Healthlaparoscopygynecologic oncologySettore MED/40 - Ginecologia E Ostetriciaminimally invasive surgerycervical cancer; endometrial cancer; gynecologic oncology; indocyanine green; laparoscopy; minimally invasive surgery; pelvic lymphadenectomy; robotic surgery
researchProduct

Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic

2021

Objective Coronavirus disease 2019 (COVID-19) outbreak has correlated with the disruption of screening activities and diagnostic assessments. Endometrial cancer (EC) is one of the most common gynecological malignancies and it is often detected at an early stage, because it frequently produces symptoms. Here, we aim to investigate the impact of COVID-19 outbreak on patterns of presentation and treatment of EC patients. Methods This is a retrospective study involving 54 centers in Italy. We evaluated patterns of presentation and treatment of EC patients before (period 1: March 1, 2019 to February 29, 2020) and during (period 2: April 1, 2020 to March 31, 2021) the COVID-19 outbreak. Results M…

medicine.medical_specialtyendometrial neoplasmsCoronavirus disease 2019 (COVID-19)Endometrial Cancer; COVID-19; Uterine cancer; SARS-CoV-2covid-19; endometrial cancer; sars-cov-2; uterine cancer; female; humans; pandemics; retrospective studies; sars-cov-2; covid-19; endometrial neoplasmspandemicsEndometrial CancerNOCOVID-19; Endometrial Cancer; SARS-CoV-2; Uterine cancerRetrospective StudiePandemicmedicineUterine cancerhumansPatterns of carePandemicObstetricsbusiness.industrySARS-CoV-2Endometrial cancerObstetrics and GynecologyCOVID-19General Medicinemedicine.diseaseEndometrial Neoplasmsretrospective studiesSettore MED/40 - GINECOLOGIA E OSTETRICIAfemaleOncologyOriginal ArticleFemalebusinessHuman
researchProduct

The Prognostic Characteristics and Recurrence Patterns of High Grade Endometrioid Endometrial Cancer: A Large Retrospective Analysis of a Tertiary Ce…

2023

High grade endometrioid endometrial cancer (HGEEC) is a heterogeneous group of tumors with unclear prognostic features. The aim of the present study is to evaluate the independent risk factors for recurrence and mortality and to describe the recurrence patterns of HGEEC. Ninety-six consecutive cases of HGEEC treated with primary surgery in a single Tertiary Center were retrospectively reviewed. Clinicopathological and treatment details were recorded, and all patients were closely followed up. Disease-free, overall and cancer-specific survival rates were 83.8%, 77.8% and 83.6%, respectively. Cervical stromal involvement was independently related to recurrence (HR = 25.67; 95%CI 2.95–223.30; …

recurrenceEndometrioid endometrial cancerPrognosiendometrioid endometrial cancer; grade 3; high grade; prognosis; recurrenceRecurrence.General MedicineprognosisGrade 3high gradeSettore MED/40 - Ginecologia E Ostetricia
researchProduct